The FDA has cleared the first lab diagnostic test to aid in the early detection of Alzheimer's disease.
May 5, 2022 – The FDA has cleared the first in vitro diagnostic to aid in the early detection of Alzheimer's disease .
"With the Lumipulse test, there is a new option that can typically be completed the same day and can give doctors the same information regarding brain amyloid status, without the radiation risk, to help determine if a patient's cognitive impairment is due to Alzheimer's disease," he said. The Lumipulse test measures the ratio of β-amyloid 1-42 and β-amyloid 1-40 concentrations in human cerebral spinal fluid . A positive Lumipulse G β-amyloid Ratio test result is consistent with the presence of amyloid plaques, similar to that revealed in a PET scan. A negative result is consistent with a negative amyloid PET scan result.
The samples were tested by the Lumipulse G β-amyloid Ratio and compared with amyloid PET scan results. In this clinical study, 97% of individuals with Lumipulse G β-amyloid Ratio positive results had the presence of amyloid plaques by PET scan and 84% of individuals with negative results had a negative amyloid PET scan.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA approves marketing for new Alzheimer's early detection testThe Lumipulse G β-Amyloid Ratio (1-42/1-40) test is available at clinical laboratories nationwide for adult patients aged 55 years and older who are presenting with cognitive impairment and being evaluated for Alzheimer’s disease and other causes of cognitive decline.
Les mer »
FDA limits Johnson & Johnson's COVID vaccine to some people due to blood clot riskThe chance of dying after receiving the Janssen vaccine is about 1:2,000,000. But with multiple COVID-19 vaccines available, the FDA is limiting the use of the J&J vaccine.
Les mer »
FDA limits Johnson & Johnson vaccine; New York City not ruling out return of mask mandatesThere are growing concerns as new data shows hospitalizations and deaths from COVID are tracking higher for the first time in months.
Les mer »
FDA limits J&J COVID-19 vaccine authorization due to blood clot riskThe Food and Drug Administration narrowed its use authorization for Johnson & Johnson’s single-dose COVID-19 vaccine due to risks of severe blood clotting, a move that comes months after an initial warning from health officials.
Les mer »
FDA restricts Johnson & Johnson COVID-19 vaccine due to blood clot riskThe Food and Drug Administration said the shot should only be given to adults who cannot receive a different vaccine or specifically request J&J's vaccine.
Les mer »